Citations

Clear

4 citation(s) found for "Dholaria, Hetal".

ID #950 CURE-ETMR, a Prospective, International, Molecularly Guided Trial Utilizing Centralized Screening and Risk-Adapted Assignment for Infants with Rare Embryonal Brain Tumors
Khan, Sara, Zezschwitz, Barbara von, Johann, Pascal, Sturm, Dominik, Dholaria, Hetal, Kool, M, Huang, Annie, Thomas, Diana, Mathew, Mariam, Cottrell, Catherine, Parbhoo, Kareesma , Mahajan, Anita , Timmermann, Beate, Palmer, Joshua, Raghuram, Nikhil, Senapati, Akanksha , Crotty, Erin, Moscato, Emily, Hoskinson, Kristen, Gerhardt, Cynthia, Rodriguez, Diana, McAllister, Aaron, Biswas, Asthik, Bhatiaa, Aashim, Troyer, Kelsey, Geyer, Susan, Salloum, Ralph, Fouladi, Maryam, Gottardo, Nick, Zezschwitz, Barbara von, Sturm, Dominik , Valvi, Santosh , Endersby, Raelene , Kool, Marcel , Mathew, Mariam, Cottrell, Catherine E. , Schieffer, Kathleen M. , Timmermann, Beate , Gojo, Johannes , Crotty, Erin E. , Moscato, Emily L. , Hoskinson, Kristen R. , Bison, Brigitte , Biswas, Asthik , Tietze, Anna , Fouladi, Maryam

Mayo Clinic

Neuro-Oncology Pediatrics | June 24, 2026 | Volume: 2 | Issue: Supplement_1 | Pages: No page available

10.1093/neuped/wuag026.410 Get It

Abstract Embryonal tumors with multilayered rosettes (ETMR) are rare, highly aggressive tumors of infancy with extremely poor outcomes and no established standard of care therapy. ETMRs were recognized as a distinct molecular entity in 2016, however, the absence of prospective, biology-driven clinical trials has limited translation of these insights into standardized, risk-adapted treatment approaches for this vulnerable population. To address this gap, the Collaborative Network for Neuro-oncology Clinical Trials (CONNECT) developed CURE(Clinical trial advancing Understanding of Rare Embryonal Brain Tumors), an international, multi-institutional, molecularly guided umbrella trial. All patients enroll through the centralized CURE-Screening protocol, which provides rapid comprehensive molecular profiling with real-time central pathology, molecular, and radiographic review to confirm diagnosis, define molecular subtype, and determine eligibility and assignment to disease-specific treatment arms. CURE-ETMR represents the first disease-specific arm to open within this platform. Following centralized screening, children with newly diagnosed ETMR are assigned to clinically defined risk strata using integrated molecular, radiographic, and clinical criteria. Patients will be treated using a risk-adapted multimodal approach in which we prioritize maximal safe surgical resection with consideration of second-look surgery based on centralized imaging review; administer induction chemotherapy followed by consolidation with high-dose chemotherapy and autologous hematopoietic cell rescue or dose-intensified chemotherapy, selectively incorporate radiation sparing approach or early focal radiotherapy for patients with unresectable residual disease or brainstem involvement; deliver intrathecal chemotherapy for leptomeningeal prophylaxis; and include biologically informed maintenance therapy. In parallel, protocol-required longitudinal collection of tumor tissue, cerebrospinal fluid, blood, and advanced neuroimaging supports integrated molecular, liquid biopsy, and imaging biomarker analyses to identify predictors of treatment response, resistance, and relapse. Primary objectives include evaluation of feasibility, safety, progression-free survival, and overall survival compared with molecularly annotated historical cohorts. This centralized screening to assignment framework establishes a scalable model for prospective, biology-driven trials in rare embryonal brain tumors.
GCT-05. UPDATED REPORT ON TREATMENT MODALITIES IN METASTATIC GERMINOMA IN CHILDREN: A MULTI-INSTITUTIONAL ANALYSIS
Thia, Alexia, Su, Jack M., MacDonald, Shannon M. , Perkins, Stephanie M., Govender, Dinisha , Foo, Jen Chun , Rajagopal, Revathi , O’Halloran, Katrina , Sleightholm, Richard, Lafay‐Cousin, Lucie , Cansanay, Rose Daynielle A, Schlosser, Mary-Pat , Cappellano, Andréa Maria , Dassi, Natália , Fisher, Michael J. , Graham, Richard , Baglivo, Sofía Jares, Ronsley, Rebecca , Khan, Sara , Magnum, Ross, Hoffman, Lindsey M. , Knowles, Truman , Mueller, Sabine , Zaghloul, Mohamed S. , Abdelhaleem, Nada A, El‐Ayadi, Moatasem , Abdelbaki, Mohamed S , Shatara, Margaret , Abu-Arja, Mohammad H , Gorsi, Hamza S. , Dholaria, Hetal , Schwartz, Jonathan, Bartels, Ute , Amayiri, Nisreen Yousef , Yılmaz, Yasin , Czogała, Małgorzata , Mastronuzzi, Angela , Michaiel, George

Mayo Clinic

Neuro-Oncology | June 18, 2024 | Volume: 26 | Issue: Supplement_4 | Pages: 0-0

10.1093/neuonc/noae064.260 Get It

Abstract BACKGROUND Primary intracranial germ cell tumors (GCTs) are rare heterogeneous tumors; germinoma accounts for two-thirds of cases. While neoadjuvant chemotherapy followed by response-based reduced radiotherapy dose and field is the established approach for managing localized CNS germinomas, controversy persists regarding the treatment of primary metastatic disease. Additionally, limited research exists on the utilization of neoadjuvant chemotherapy in primary metastatic germinoma. METHODS A retrospective multi-institutional analysis was conducted to assess overall survival (OS) and event-free survival (EFS) among patients diagnosed with metastatic germinoma who were treated with various modalities. RESULTS We identified 88 patients, including 63 males and 25 females. The median age at presentation was 13.5 years. All patients, who had undergone both brain and spine MRIs, had their diagnoses confirmed through a biopsy, positive CSF cytology, and/or positive CSF tumor markers at presentation. Primary Tumor location was pineal (n=37), suprasellar (n=27), bifocal (n=14) and others (n=9). Eight patients underwent subtotal resection. Craniospinal irradiation (CSI; 21-24 Gy) was administered to 71 patients (81%), while eight patients (9%) received whole ventricular irradiation (WVI; 23.4-30 Gy). Whole brain radiation was given to four patients (5%; 24 Gy), and two patients (2%) had unknown fields. Boosts to primary and/or metastatic sites were administered in all but seven patients. Notably, thirty patients (34%) received CSI without neoadjuvant chemotherapy. At the end of therapy, 69 patients had complete response, 10 partial response and the response was unknown in six. Three patients did not receive irradiation, all died of disease progression. The median follow-up was 64 months (range 6-159 months), yielding an OS of 96.6%. Ongoing multi-institutional data collection and analysis will be presented at the meeting. CONCLUSION Our study is one of the largest studies to date in metastatic germinoma and may provide insight into the role of neoadjuvant chemotherapy with lower CSI doses.
LGG-21. Durability of response to targeted therapies in pediatric low-grade gliomas: A multi-institution retrospective review
Reiners, Stephanie, Ogle, Andrea, Cluster, Andrew , Govender, Dinisha , Nagabushan, Sumanth , Abdelbaki, Mohamed S , Navalkele, Pournima , Cantor, Evan , Chaturvedi, Sneha M. , Meyer, Ashley , Brossier, Nicole Marie , Dholaria, Hetal , Schwartz, John A. , Shatara, Margaret

Mayo Clinic

Neuro-Oncology | June 3, 2022 | Volume: 24 | Issue: Supplement_1 | Pages: i92-i92

10.1093/neuonc/noac079.335 Get It

Abstract Background: The discovery of the driving oncogenic alterations in pediatric low-grade gliomas (pLGGs) has shifted our focus towards management with targeted therapies, especially in relapsing or progressive disease. Limited data is available on the durability of response to targeted therapy in pLGGs once the therapy has ceased. Methods: Multi-institutional retrospective chart review of patients with pLGGs younger than 25 years, between 2010-2021, was undertaken to evaluate the durability of response to targeted therapy and determine risk factors associated with disease progression after cessation of therapy. Results: Current analysis included 18 patients from two centers. Seven (39%) had neurofibromatosis type-1 (NF-1). Diagnoses included: optic pathway glioma (OPG) (6/18, 33%), pilocytic astrocytoma (8/18, 44%), diffuse fibrillary astrocytoma (1/18), ganglioglioma (1/18), glioneural neoplasm (2/18). Sixteen patients received at least one prior line of chemotherapy (range 1-5). Targeted agents included trametinib (50%), selumetinib (5%), binimetinib (22%), vemurafenib (11%) and everolimus (11%). Median time on therapy was 351 days (range 29-979 days). All, but one patient had residual intracranial findings at the end of therapy: eight patients (44%) had stable disease, while ten required additional therapy; 50% were NF-1 patients with OPG. Median time to progression was 203 days (range 29-615 days). Of those who did not require any additional therapies, 50% had suprasellar tumors. Genomic data was available for twelve patients; BRAF-KIAA1549 fusion was the most common genomic alteration. Others included mutations in KRAS, BRAF (V600E), PTPN11, SOX6-RAF1 fusion, NF-1, and a patient with FGFR1, KMT2C, and PTPN11 alterations. Conclusion: Preliminary analysis demonstrates that despite initial response, the majority of patients required additional line of therapy. Patients with NF-1 and OPGs tend to progress after discontinuing therapy, while suprasellar non-NF1 pLGGs tend to develop sustained response to targeted therapies. Additional multi-institutional analysis is underway and will be presented at the meeting.
GCT-05. Multi-institutional analysis of treatment modalities in metastatic germinoma in children
MacDonald, S., Reiners, Stephanie, Govender, Dinisha , Nagabushan, Sumanth , Schwartz, Jonathan , Foo, Jen Chun , Rajagopal, Revathi, Perkins, Stephanie M., Zaghloul, Mohamed S. , Abdelhaleem, Nada A, El‐Ayadi, Moatasem , Abdelbaki, Mohamed S , Shatara, Margaret , Abu-Arja, Mohammad H , Gorsi, Hamza S. , Dholaria, Hetal , Rajagopal, Revathi , Bartels, Ute

Mayo Clinic

Neuro-Oncology | June 3, 2022 | Volume: 24 | Issue: Supplement_1 | Pages: i54-i55

10.1093/neuonc/noac079.199 Get It

Abstract BACKGROUND: Primary intracranial germ cell tumors (GCTs) are rare heterogeneous tumors, with germinoma accounting for two-thirds of cases. Neoadjuvant chemotherapy with response-based reduced radiotherapy dose and field has become the standard management of localized CNS germinomas, however, treatment of primary metastatic disease has remained controversial. Furthermore, there is limited published research on the use of neoadjuvant chemotherapy in primary metastatic germinoma. METHODS: We performed a retrospective multi-institutional data collection and analysis of patients diagnosed with metastatic germinoma since 2000 to assess the overall survival (OS) and event-free survival (EFS) of the different treatment modalities administered. RESULTS: We identified 78 patients with germinoma, in two tertiary care centers, of which nine patients (11.5%; eight males) had metastatic disease. The median age at presentation was 13.3 years. All patients had a biopsy at presentation confirming the diagnosis. Three patients had positive CSF cytology (M1). Six patients received craniospinal irradiation (CSI) with boost to primary and metastatic sites, of which five patients received total CSI dose of 24 Gy, while the dose was unknown for one patient. One patient required one cycle of chemotherapy prior to CSI due to worsening visual changes, which subsequently resolved. One patient received two cycles followed by whole ventricular irradiation (WVI) of 23.4 Gy with a boost to the primary bed. One patient received WVI without neoadjuvant chemotherapy. One patient developed anoxic brain injury and only received chemotherapy. He died of recurrent progressive disease 15 months post-diagnosis. The median follow-up time was 77.5 months (range 15-130.5 months), with an OS of 88.9%. Further multi-institutional data collection and analysis is underway and will be presented at the meeting. CONCLUSION: We anticipate our results may elucidate the role of neoadjuvant chemotherapy in the treatment of metastatic germinoma, and whether when combined with lower CSI doses did not compromise EFS/OS.